Clinical Trial Update: Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

This Phase 2 trial comparing endocrine therapy with fulvestrant plus palbociclib versus aromatase inhibitor therapy in older patients with hormone receptor-posi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anastrozole ( Arimidex ) (anastrozole)
• Exemestane ( Aromasin ) (exemestane)
• Fulvestrant (Faslodex) (fulvestrant)
• Letrozole ( Femara ) (letrozole)
• Palbociclib (Ibrance) (palbociclib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Estrogen Receptor and/or Progesterone Receptor Positive, HER2/Neu Negative | Phase 2 | Status: COMPLETED